Here are the 10-K annual reports from Jazz Pharmaceuticals, Inc. (JAZZ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow JAZZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAZZ filings page.
Jazz Pharmaceuticals plc filed an Amendment No. 1 to its 2025 annual report to add Part III information normally drawn from its proxy, update the cover page and exhibit list, and provide new CEO/CFO certifications. The company reported an aggregate market value of non‑affiliate equity of about $6.25 billion as of June 30, 2025, and 62,738,815 ordinary shares outstanding as of April 15, 2026.
Jazz highlights record 2025 performance with strong product sales, including Xywav $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million, plus oncology contributions from Zepzelca, Rylaze/Enrylaze, Modeyso and Ziihera. The board describes a pay‑for‑performance design: 2025 bonuses funded at 150% of target based on corporate goals, while 2023–2025 PSUs paid at 94% of target after operational scoring and relative TSR adjustments.
The amendment details a staggered board, refreshed committee memberships and extensive biopharma, financial and governance experience among directors and executives. It also outlines executive incentives tied to multi‑year commercial, pipeline and capital deployment objectives, supported by stock ownership guidelines, a clawback policy, insider‑trading controls and change‑in‑control and severance plans.
Jazz Pharmaceuticals plc describes a rare-disease focused biopharma business built around neurology and oncology therapies, anchored by its oxybate sleep franchise and epilepsy and cancer drugs. The company emphasizes Xywav and Epidiolex/Epidyolex as its largest products, with Xywav generating $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million of net product sales in 2025.
Oncology growth is led by Zepzelca, with $307.3 million of 2025 net sales, and newer launches Ziihera and Modeyso, both approved under FDA’s accelerated approval pathway for difficult-to-treat cancers. Rylaze adds another $402.9 million, and legacy Xyrem has declined to $146.0 million amid generic and authorized generic competition.
The report highlights revenue diversification away from high-sodium Xyrem, extensive global commercialization, and a deep pipeline including HER2-targeted antibody zanidatamab, additional Vyxeos studies, early-stage oncology assets JZP815 and JZP898, and expanded indications for Epidiolex. Jazz also underscores investment in R&D talent, scalable operations, and an inclusion-focused culture across roughly 2,890 employees.